logo
Plus   Neg
Share
Email

Astellas Pharma Gets Positive CHMP Opinion For XOSPATA

Astellas Pharma Inc. said that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA has adopted a positive opinion recommending the oral once-daily therapy XOSPATA or gilteritinib as a monotherapy for the treatment of adult patients who have relapsed or refractory (resistant to treatment) acute myeloid leukemia or AML with a FLT3 mutation (FLT3mut+).

If approved by the European Commission, gilteritinib has the potential to improve treatment outcomes for AML patients with the most common mutations - FLT3 internal tandem duplication (ITD) and FLT3 tyrosine kinase domain (TKD) - and would be one of the few advances for the treatment of AML in Europe over the past 40 years.

Gilteritinib received accelerated assessment from the EMA, which allowed the CHMP to reduce the timeframe for approval.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Intel Corp. said it is probing into the hack of its fourth-quarter earnings report that prompted the chipmaker to release its earnings statement ahead of schedule. The company, which was scheduled to release the results after the market closed, released it before the market closing on Thursday. Google parent Alphabet decided to drop its Internet balloon project Loon that was launched with the idea of providing Internet access to rural areas and providing last mile connectivity. In a blog post, Loon CEO Alastair Westgarth said they have not found a way to get the costs low enough to build a long-term, sustainable business, despite gaining a number of interested partners along the way. American Airlines announced the launch of Flagship Cellars, its home delivery service for premium wines usually available onboard. The airline's move is said to be due to the excess wine it has amid the weakness in air travel demand following the coronavirus pandemic crisis. The company expects the new at-home wine program to generate about $40,000 to $50,000 in sales during the first quarter.
Follow RTT